Advertisement

Topics

Achillion Pharmaceuticals stock climbs on promising Phase 2 data for its blood-disorder treatment

05:45 EDT 17 May 2019 | Proactive Investors

The company is part of a study to treat paroxysmal nocturnal hemoglobinuria, a rare disease that causes red blood cells to break apart

Original Article: Achillion Pharmaceuticals stock climbs on promising Phase 2 data for its blood-disorder treatment

NEXT ARTICLE

More From BioPortfolio on "Achillion Pharmaceuticals stock climbs on promising Phase 2 data for its blood-disorder treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...